PureTech Health plc (LSE:PRTC)'s Founded Entity Seaport Therapeutics (NASDAQ:SPTX) reported positive multiple‑ascending dose Phase 1 results for GlyphAgo, supporting the planned advancement of the program into two parallel Phase 2 trials.
Seaport Therapeutics, a clinical‑stage neuropsychiatric therapeutics company, said seven‑day repeat dosing achieved therapeutic agomelatine exposures while reducing liver exposure and produced no liver‑related adverse events in the 174‑participant Phase 1 programme.
"We believe these results substantially derisk our future clinical development approach and strengthen the differentiated profile of GlyphAgo," said Daphne Zohar, Co‑Founder and Chief Executive Officer of Seaport Therapeutics.
In earlier parts of the trial Seaport reported GlyphAgo increased agomelatine bioavailability 6.8‑fold versus unmodified agomelatine in the crossover cohort, showed about a 10‑fold reduction in PK variability, and produced a 9.6-14.5‑fold increase in dose‑normalised exposure in separate single‑ascending‑dose cohorts.
Across all dose levels in the multiple‑ascending dose portion GlyphAgo was well tolerated with no serious or severe adverse events and no clinically significant changes in liver‑related laboratory parameters.
Seaport expects to start a Phase 2a proof‑of‑pharmacology trial in the second half of 2026 with topline data in early 2028 and a potentially registration‑enabling Phase 2b in the first half of 2027 with topline data by the end of 2028.
